Navigation Links
Catabasis Closes $32.4 Million Series B Financing
Date:11/14/2013

CAMBRIDGE, Mass., Nov. 15, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals, Inc., today announced it has completed a $32.4 million Series B financing round led by new investor Lightstone Ventures. A leading public crossover fund and all current Catabasis investors, including SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures, also participated in the financing.

"This investment reflects our confidence in Catabasis' pipeline of SMART Linker conjugates as much as our belief in management's ability to successfully advance its clinical candidates," said Jean George, partner of Lightstone Ventures. "Catabasis has achieved a number of important milestones in the past year including positive data from Phase 1 studies of both CAT-2003 and CAT-1004. We look forward to working with the management team as they complete the ongoing Phase 2 trial for CAT-2003 and seek to advance the rest of the pipeline."

Catabasis plans to use proceeds from this financing to support the development of its lead compound, CAT-2003, a modulator of the lipid synthesis pathway, which is currently in a Phase 2 clinical trial in patients with hypertriglyceridemia and in combination with statins in patients with hypercholesterolemia. Catabasis also plans to use the proceeds to support the continued clinical and pre-clinical development of other SMART Linker conjugates in the pipeline.

"We are tremendously excited about the progress we've made with our pipeline thus far, having reported positive Phase 1 data for both CAT-2003 and CAT-1004 and having advanced CAT-2003 to Phase 2," said Jill Milne, Ph.D., co-founder and chief executive officer of Catabasis. "This financing enables Catabasis to continue to execute on the promise of its pipeline for dyslipidemias and diseases involving chronic inflammation."  '/>"/>

SOURCE Catabasis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia
2. Catabasis Pharmaceuticals Announces Issuance of Patents for CAT-1000 and CAT-2000 Series
3. Catabasis Names Ian Sanderson Chief Financial Officer
4. Independa Closes Convertible Note Funding at $2.35 Million
5. Stereotaxis Closes $18.5 Million Private Placement Financings
6. Boston Scientific Closes Cameron Health Acquisition
7. C8 MediSensors Closes $19 million Preferred Stock Financing
8. Igenica Closes $33 Million in Series C Funding
9. BONESUPPORT Closes Second Tranche of Funding
10. PTC Therapeutics Closes $30 Million Financing
11. Chiasma Closes $38.5 Million Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... China, Nov. 26, 2014 China Nepstar Chain ... "Company"), a leading retail drugstore chain in China based ... its unaudited financial results for the third quarter ended September ... 30, 2014: , Same store sales increased by ... , Revenue increased by 8.1% to RMB738.3 million (US$120.3 million) ...
(Date:11/24/2014)... 24, 2014 Luoxis Diagnostics, Inc., a ... today announced the presentation of three clinical and ... a broadly applicable and robust research tool capable ... in response to injury, illness, or stress.  In ... with Luoxis, academic and pharmaceutical research partners, RedoxSYS ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5
... According to Millennium Research Group (MRG), the global authority ... device market was valued at $41 million in 2010, ... awareness of health issues surrounding obesity, coupled with an ... will drive significant growth in the gastric band market ...
... 28 Decision Resources, one of the world,s ... healthcare issues, finds that oncologists will be the ... specialties because of their lower clinical trial requirements. ... Physician Perspectives on Biosimilar G-CSFs and ...
Cached Medicine Technology:While Ethicon Endo-Surgery and Allergan Remain Front-Runners in the $41 Million Gastric Band Market, Other Competitors Battle for Third Place, According to Millennium Research Group 2Oncologists Will Be More Aggressive In Adopting Biosimilars Compared With Other Specialties 2
(Date:11/26/2014)... November 26, 2014 Increasing demand ... include image guided surgeries has paved way for ... Rising incidence of various types of cancers and ... increase in demand for these owing to their ... contrast media injectors market can also be attributed ...
(Date:11/26/2014)... November 26, 2014 German scientists say ... science can cause mesothelioma that looks and acts similar ... new article on the research. Click here to ... Institute for Toxicology and Experimental Medicine in Hannover injected ... all of the rats eventually developed mesothelioma , ...
(Date:11/26/2014)... November 26, 2014 For its ... published The AIS Report on Blue Cross and Blue ... Inc. on the varied strategies the two Blues plans ... compliance with treatments for sleep apnea, ranging from brick-and-mortar ... because it’s linked to increased rates of a variety ...
(Date:11/26/2014)... November 26, 2014 With Thousand Oaks ... dollars, the prosthodontists at the Anacapa Dental Art Institute in ... procedures can be daunting for some. , That is why ... procedures they offer. , “No dentist wants cost to come ... of teeth,” said Dr. Mamaly Reshad, partner in the Anacapa ...
(Date:11/26/2014)... 26, 2014 Sonru, the video interviewing ... Chief Operating Officer and Chief Marketing Officer, in addition ... , Jeff Jones has been appointed as Chief ... takes the role of Chief Marketing Officer. , Mr ... whose 25-year career includes senior roles with The Walt ...
Breaking Medicine News(10 mins):Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 4Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 5Health News:Sonru Expansion continues with appointment of new executive team and opening of new London base 2
... Plan Members Drop Coverage for multiple Reasons; Integrated Retention Strategy ... Balance Sheet. , ... Orlando, FL ... of ConnextionsHealth provides both good and bad news for health ...
... U.S, NAPWA and POZ reinvigorate AIDS activism -WASHINGTON, March ... (NAPWA) and POZ magazine today announced the ... Principles Project. The project aims to encourage a ... self-empowerment manifesto written in 1983 by a group of ...
... Lead Lilly USA Business-to-Business Organization and Oversee Sales and ... Include Lilly USA Diabetes Business UnitINDIANAPOLIS, March 2 ... today announced that Alex M. Azar II, currently senior ... the top leadership role in Lilly,s U.S. Business-to-Business organization. ...
... its part to help fight AIDS in Africa with ... of National Sleep Awareness Week, Coherence Resources, Inc. provided ... they need: adequate sleep. Malaria medications taken by ... from Coherence Resources helps the volunteers cope with the ...
... Milan, Italy----Cowen and Company 29th Annual Health Care Conference in ... (Nasdaq: TSPT ) announced today that the Company ... , Glenn A. Oclassen, ... 2009, to be held at the Milano Convention Centre (MIC) ...
... Industries, Inc. (Nasdaq: HRLY ) announced today that ... $1 million from the U. S. Air Force for the ... The awards are for the production of transmit microwave assemblies ... components for use in the APG-68 radar system on various ...
Cached Medicine News:Health News:Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows 2Health News:Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows 3Health News:The National Association of People with AIDS (NAPWA) and POZ Magazine Partner to Launch The Denver Principles Project 2Health News:The National Association of People with AIDS (NAPWA) and POZ Magazine Partner to Launch The Denver Principles Project 3Health News:Lilly Announces Leadership Changes 2Health News:Lilly Announces Leadership Changes 3Health News:Sleepless in Botswana 2Health News:Sleepless in Botswana 3Health News:Transcept Pharmaceuticals to Present at Two Upcoming Conferences 2Health News:Transcept Pharmaceuticals to Present at Two Upcoming Conferences 3Health News:Herley Lancaster Awarded $1.0 Million in New Contracts 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: